Davis Polk, Goodwin Steer $1.1B Novo Nordisk Acquisition
Davis Polk & Wardwell LLP-led Novo Nordisk will acquire Goodwin Procter LLP-advised Forma Therapeutics Holdings Inc., which develops treatments for sickle cell disease and rare blood disorders, for a total equity...To view the full article, register now.
Already a subscriber? Click here to view full article